Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO for chemotherapy-induced thrombocytopenia after acute leukemia treatment
ChiCTR1900023025Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- May 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia (CIT) (2 arms), sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Platelet count and Duration of platelet count below 20 x 10^9/L. Planned start May 2019; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR1900023025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023025.